Enliven net loss widens 28.2% to $32.5 million in Q2 FY26

Reuters2026/08/05 20:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Enliven Therapeutics posted a Q2 net loss of USD 32.49 million, worsening from USD 25.34 million a year earlier.
RD expenses climbed to USD 29 million from USD 21.5 million year-on-year; GA costs rose to USD 8.21 million from USD 7.09 million.
Cash, cash equivalents and marketable securities totaled USD 895.2 million at June 30, with runway expected into 2030.
Updated Phase 1 ELVN-001 data showed 61% overall MMR, 48% MMR by 24 weeks in the 80 mg QD Phase 1b cohort.
FDA alignment set 80 mg QD for the Phase 3 ENABLE-2 design, with trial initiation expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608051605PR_NEWS_USPR_____LA18519) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Enliven net loss widens 28.2% to $32.5 million in Q2 FY26

You may also like

Crypto prices